

# NEW OPTIONS IN HCV THERAPY:

UPDATE  
FROM  
AASLD  
2014

**NEW  
OPTIONS** IN HCV  
THERAPY:

UPDATE  
FROM  
AASLD  
2014

Wednesday, January 28, 2015  
CUT Steakhouse, Chicago, IL

---

**Nancy Reau, MD**  
Associate Professor of Medicine  
University of Chicago

# Agenda

- 6:15 – 6:30 PM Registration and Pre-Assessment
- 6:30 – 6:50 PM Case 1: Liver Failure
- 6:50 – 7:00 PM Discussion
- 7:00 – 7:20 PM Case 2: Cirrhosis
- 7:20 – 7:30 PM Discussion
- 7:30 – 7:50 PM Case 3: Genotype 1 Naive
- 7:50 – 8:00 PM Discussion
- 8:00 – 8:20 PM Case 4: Genotype 3
- 8:20 – 8:30 PM Discussion
- 8:30 – 8:45 PM Post-Assessment

# Learning Objectives

As a result of this educational activity, participants will be able to:

1. Delineate which subgroups of patients with HCV infection are likely to benefit from HCV therapy that includes a direct antiviral
2. Implement cost-effective procedures to stage liver disease in patients with HCV infection, before and during antiviral treatment
3. Select the best therapy for HCV patients with specific disease characteristics using evidence-based data
4. List common adverse events associated with HCV therapy that includes a direct antiviral
5. Discuss which HCV therapies may be appropriate for pre- and post- liver transplant patients

# Disclosures

Name	Role	Financial Relationship Disclosures
Nancy Reau, MD Associate Professor of Medicine University of Chicago	Presenter	AbbVie, Gilead, Idenix (Consultant); AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Vertex Pharmaceuticals Inc. (Principal Investigator (PI))
Nezam H. Afdhal, MD Professor of Medicine, Harvard Medical School, Chief of Hepatology, Beth Israel Deaconess Medical Center	Content Developer	AbbVie, Achillion, Boehringer-Ingelheim, Echosens, Gilead Sciences, Glaxosmithkline, Janssen, Kadmon, Ligand, Medgenex, Inc, Merck, Novartis, Springbank, Vertex Pharmaceuticals Inc. (Consultant); AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Vertex Pharmaceuticals Inc. (Principal Investigator (Pi)); Springbank (Stockholder /Other Ownership Interest Holder)
Ira Jacobson, MD Chief of the Division of Gastroenterology and Hepatology Vincent Astor Distinguished Professor of Medicine Medical Director Center for the Study of Hepatitis C Weill Medical College of Cornell University	Content Developer	AbbVie, Achillion, Alnylam, Bristol-Myers Squibb, Enanta, Genentech, Gilead, Janssen, Merck (Consultant); AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck (Independent Contractor/Researcher); AbbVie, Bristol Myers Squibb, Genentech, Gilead, Janssen (Teacher/Speaker)

# Disclosures

Name	Role	Financial Relationship Disclosures
Jane Henderson	Planner	No relevant financial relationships to disclose
Danielle Hepting	CME Staff	No relevant financial relationships to disclose
Leslie Jacus	Planner	No relevant financial relationships to disclose
Donna McMullen	Planner	No relevant financial relationships to disclose
Adnan Said, MD	Content Reviewer	No relevant financial relationships to disclose

# Meeting Materials

- Pre-Test
- Brochure
- Disclosures
- CME Credit and Slides
- Notes pages
- Post-Test

# NEW OPTIONS IN HCV THERAPY:

UPDATE  
FROM  
AASLD  
2014